Impact of high-throughput screening in biomedical research
The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Abstract
High-throughput screening (HTS) has been postulated in several quarters to be a contributory factor to the decline in productivity in the pharmaceutical industry. Moreover, it has been blamed for stifling the creativity that drug discovery demands. In this article, we aim to dispel these myths and present the case for the use of HTS as part of a proven scientific tool kit, the wider use of which is essential for the discovery of new chemotypes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Cell-based phenotypic screening of chemical libraries represents a powerful tool to identify new potential drugs48.”
From Identification and characterization of Cardiac Glycosides as senolytic compounds (2019) · cites this paper as [48]
Citations
Cites
Zhang, J.-H., Chung, T. D. Y., & Oldenburg, K. R. (1999) · SLAS Discovery · doi:10.1177/108705719900400206 · Cited by 6,847 · cited 1×
“HTS laboratories have pioneered and implemented rigorous quality assurance methods, such as Z′ trend monitoring”
MethodCan the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566 · cited 1×
“These efforts typically take 2–3 years in most drug discovery companie”
BackgroundDrug repositioning: identifying and developing new uses for existing drugs
Ashburn, T. T., & Thor, K. B. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1468 · Cited by 3,237 · cited 1×
“There have been numerous analyses of pharmaceutical industry productivity, and several of these have blamed high-throughput screening (HTS) as a factor undermining the creativity that has sustained the industry over the past centur”
BackgroundDiscovery and development of sorafenib: a multikinase inhibitor for treating cancer
Wilhelm, S., Carter, C., Lynch, M., Lowinger, T., Dumas, J., Smith, R. A., Schwartz, B., Simantov, R., & Kelley, S. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2130 · Cited by 1,829
Lessons from 60 years of pharmaceutical innovation
Munos, B. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2961 · Cited by 1,207
Dorr, P., Westby, M., Dobbs, S., Griffin, P., Irvine, B., Macartney, M., Mori, J., Rickett, G., Smith-Burchnell, C., Napier, C., et al. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.11.4721-4732.2005 · Cited by 1,152
Hit and lead generation: beyond high-throughput screening
Bleicher, K. H., Böhm, H.-J., Müller, K., & Alanine, A. I. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1086 · Cited by 1,056
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect
Gao, M., Nettles, R. E., Belema, M., Snyder, L. B., Nguyen, V. N., Fridell, R. A., Serrano-Wu, M. H., Langley, D. R., Sun, J.-H., O’Boyle II, D. R., et al. (2010) · Nature · doi:10.1038/nature08960 · Cited by 939 · cited 1×
“This approach was used to discover compounds that inhibited hepatitis C virus replication and, after consequent optimization, the approach yielded efficacious clinical candidates with a broad genotype coverag”
MethodA Specific Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase
Fry, D. W., Kraker, A. J., McMichael, A., Ambroso, L. A., Nelson, J. M., Leopold, W. R., Connors, R. W., & Bridges, A. J. (1994) · Science · doi:10.1126/science.8066447 · Cited by 806
Research works printed but not linked: 5
- Landers, P. Human Element: drug industry's big push into technology falls short — testing machines were built to streamline research — but may be stifling it — officials see payoff after 2010. The Wall Street Journal 1 (24 Feb 2004).
- Mullin, R. As high-throughput screening draws fire, researchers leverage science to put automation into perspective. Chem. Eng. News 82, 23–32 (2004).
- HTStec Limited. Cellular Assay Reagents Trends 2009 Report (Cambridge, UK, 2009).
- LaMattina, J. L. (ed.) in Drug Truths: Dispelling the Myths About Pharma R&D 65–66 (John Wiley and Sons, Inc., Hoboken, New Jersey, 2009).
- Inglese, J. in Ask the Expert Forum, ACS Chemical Biology. ACS Publications [online] http://community.acs.org/ChemBiol/AsktheExpert/AsktheExpertArchive/tabid/67/Default.aspx (2008).
Cited by
Items 601–700 of 1,000
Magalhães, P. R., Reis, P. B. P. S., Vila‐Viçosa, D., Machuqueiro, M., & Victor, B. L. (2022) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.2c00372 · Cited by 17
Sánchez-Ruiz, A., & Colmenarejo, G. (2022) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.2c00888 · Cited by 17
He, F., Wang, X., Wu, Q., Liu, S.-Z., Cao, Y., Guo, X., Yin, S., Yin, N., Li, B., & Fang, M. (2023) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2023.106645 · Cited by 18
Bracken, A. K., Gekko, C. E., Suss, N. O., Lueders, E. E., Cui, Q., Fu, Q., Lui, A. C. W., Anderson, E. T., Zhang, S., & Abbasov, M. E. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.3c10741 · Cited by 19
Meller, A., Kelly, D. G., Smith, L. G., & Bowman, G. R. (2024) · Protein Science · doi:10.1002/pro.4902 · Cited by 18
“Similarly, high throughput screening with purified proteins, cell lines, or complex organoids can uncover new lead compounds (Gilmartin et al., 2014; Macarron et al., 2011; Malik et al., 2011).”
BackgroundChandraghatgi, R., Ji, H., ROSEN, G. L., & Sokhansanj, B. A. (2024) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.4c00234 · Cited by 16
From cell lines to cancer patients: personalized drug synergy prediction
Kuru, H. İ., Çiçek, A. E., & Taştan, Ö. (2024) · Bioinformatics · doi:10.1093/bioinformatics/btae134 · Cited by 16
Petersen, R. G., Quement, S. T. L., & Nielsen, T. E. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201405747 · Cited by 16
Facile One-Pot Parallel Synthesis of 3-Amino-1,2,4-triazoles
Bogolyubsky, A. V., Savych, O., Zhemera, A. V., Pipko, S. E., Grishchenko, A. V., Konovets, A. I., Doroshchuk, R. O., Khomenko, D. M., Броварец, В. С., Moroz, Y. S., et al. (2018) · ACS Combinatorial Science · doi:10.1021/acscombsci.8b00060 · Cited by 16
High-Throughput Screening of Lipidomic Adaptations in Cultured Cells
Jeucken, A., & Brouwers, J. F. H. M. (2019) · Biomolecules · doi:10.3390/biom9020042 · Cited by 16
“Valuable and often essential compound library screening has thereby come within reach for every lipidomics laboratory [58].”
BackgroundBatchDTA: implicit batch alignment enhances deep learning-based drug–target affinity estimation
Luo, H., Xiang, Y., Fang, X., Lin, W. R., Wang, F., Wu, H. R., & Wang, H. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbac260 · Cited by 16
Cholesterol sulfate as a potential inhibitor of hepatitis C virus NS3 helicase
Furuta, A., Salam, K. A., Akimitsu, N., Tanaka, J., Tani, H., Yamashita, A., Moriishi, K., Nakakoshi, M., Tsubuki, M., Sekiguchi, Y., et al. (2013) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.3109/14756366.2013.766607 · Cited by 16
Data Mining and Computational Modeling of High-Throughput Screening Datasets
Ekins, S., Clark, A. M., Dole, K., Gregory, K., McNutt, A. M., Spektor, A. C., Weatherall, C., Litterman, N. K., & Bunin, B. A. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7724-6_14 · Cited by 18
“For well over twenty years, the early stages of modern drug discovery have utilized high throughput screening (HTS) of large libraries using small molecules against target–based assays 1 .”
BackgroundHanna, N., Kicka, S., Chiriano, G., Harrison, C. F., Ouertatani-Sakouhi, H., Trofimov, V., Kranjc, A., Nitschke, J., Pagni, M., Cosson, P., et al. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.00266 · Cited by 16
“In recent years, several phenotypic screens performed in the context of infected animal host cells have identified compounds active against pathogenic mycobacteria and Legionella pneumophila (Escoll et al., 2013; Foo et al., 2018; Machelart et al., 2019).”
BackgroundThe Role of Protein Structural Analysis in the Next Generation Sequencing Era
Yue, W. W., Froese, D. S., & Brennan, P. E. (2012) · Topics in current chemistry · doi:10.1007/128_2012_326 · Cited by 18
“Its success in generating hits also depends upon target classes, robustness of the assay and propensity to deliver false positives [105].”
BackgroundRational Structure-Based Drug Design
Khanna, V., Ranganathan, S., & Petrovsky, N. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-809633-8.20275-6 · Cited by 16
The Art of Virtualizing Pharma R&D
Schuhmacher, A., Gassmann, O., Kuss, M., & Hinder, M. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.07.004 · Cited by 16
Reutlinger, M., Rodrigues, T., Schneider, P., & Schneider, G. (2013) · Angewandte Chemie · doi:10.1002/ange.201307786 · Cited by 15
Promoting GAINs (Give Attention to Limitations in Assays) over PAINs Alerts: no PAINS, more GAINs
Choo, M. Z. Y., & Chai, C. L. L. (2022) · ChemMedChem · doi:10.1002/cmdc.202100710 · Cited by 15
Salame, N., Fooks, K., El-Hachem, N., Bikorimana, J., Mercier, F., & Rafei, M. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.852143 · Cited by 18
“In fact, many anti-cancer, anti-glycemic or cardiovascular drugs found on the market nowadays were initially identi fi ed via this strategy (Macarron et al., 2011).”
BackgroundBräse, S. (2024) · Digital Discovery · doi:10.1039/d4dd00130c · Cited by 18
Using the BioAssay Ontology for Analyzing High-Throughput Screening Data
Balderud, L. Z., Murray, D., Larsson, N., Vempati, U. D., Schürer, S. C., Bjäreland, M., & Engkvist, O. (2014) · SLAS DISCOVERY · doi:10.1177/1087057114563493 · Cited by 15
“In addition, HTS is rapidly expanding in academic drug discovery.(1) HTS methods and throughput have continuously evolved over almost 30 years and are now a routine strategy for hit identification in early drug discovery.”
BackgroundChen, Y., & Tang, H. M. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-2330-4_24 · Cited by 15
“Resulting from a state-of-the-art automated facility, optimized drug-like compound libraries, and multiple quality control algorithms, hit compounds from about 50 % of HTS projects have led to the successful development of drugs in pharmaceutical pipelines [3].”
BackgroundUbiquinone modified printed carbon electrodes for cell culture pH monitoring
McBeth, C., Dughaishi, R. A., Paterson, A. W. J., & Sharp, D. (2018) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2018.04.052 · Cited by 15
Luciferase reporter assay for unlocking ligand-mediated signaling of GPCRs
Ünal, H. (2018) · Methods in cell biology · doi:10.1016/bs.mcb.2018.08.001 · Cited by 15
Meanwell, N. A., & Belema, M. (2019) · Topics in medicinal chemistry · doi:10.1007/7355_2018_47 · Cited by 15
Ring Distortion of Vincamine Leads to the Identification of Re-Engineered Antiplasmodial Agents
Norwood, V. M., Murillo-Solano, C., Goertzen, M. G., Brummel, B. R., Perry, D. L., Rocca, J. R., Chakrabarti, D., & Huigens, R. W. (2021) · ACS Omega · doi:10.1021/acsomega.1c02480 · Cited by 15
Yang, S., Shen, T., Fang, Y., Wang, X., Zhang, J., Yang, W., Huang, J., & Han, X. (2022) · Genomics Proteomics & Bioinformatics · doi:10.1016/j.gpb.2022.12.007 · Cited by 16
“, genetics [4, 5], drug discovery and development [6, 7, 3, 8].”
BackgroundBoswell, Z., Verga, J. U., Mackle, J., Guerrero‐Vázquez, K., Thomas, O., Cray, J., Wolf, B. J., Choo, Y., Croot, P. L., Hamann, M. T., et al. (2023) · Infection and Drug Resistance · doi:10.2147/idr.s395203 · Cited by 17
“This is because, in general, in-vitro-only de novo drug discovery, reliant on vast chemical libraries and expensive and extensive robotics, is a laborious and low yielding strategy.(16,17) Increasingly, in the age of big data and deep learning, molecular docking simulations are being used to narrow the space of possib…”
BackgroundCell-patterned glass spray for direct drug assay using mass spectrometry
Wu, J., Wang, S., Chen, Q., Jiang, H., Liang, S., & Lin, J. (2015) · Analytica Chimica Acta · doi:10.1016/j.aca.2015.08.020 · Cited by 15
Mahuteau‐Betzer, F. (2015) · médecine/sciences · doi:10.1051/medsci/20153104016 · Cited by 15
Discovery of a Specific Inhibitor of Pyomelanin Synthesis in Legionella pneumophila
Aubi, O., Flydal, M. I., Zheng, H., Skjærven, L., Rekand, I. H., Leiros, H. S., Haug, B. E., Cianciotto, N. P., Martínez, A., & Underhaug, J. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01589 · Cited by 15
Teitz, T., Goktug, A. N., Chen, T., & Zuo, J. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-3615-1_22 · Cited by 15
High-throughput screening and structure-based approaches to hit discovery: is there a clear winner?
Jhoti, H., Rees, S., & Solari, R. C. E. (2013) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.857654 · Cited by 15
“HTS has led to the development of a number of drugs including Tykerb (GlaxoSmithKline), Januvia (Merck) and Sprycel (Bristol-Myers Squibb) [9].”
BackgroundTargeting RNA-binding proteins with small molecules: perspectives and challenges
Konde, O. M., Balela, W. B., & Tshitenge, T. B. (2025) · Frontiers in Chemistry · doi:10.3389/fchem.2025.1649692 · Cited by 14
“However, HTS is resource-heavy and has a success rate of only around 50% (Macarron et al., 2011).”
Artificial Intelligence in Drug Discovery: Integrative Advances From Data to Therapeutic Innovation
Mehran, M. J., Mohammadzadeh, S., Bolideei, M., Barzigar, R., Haider, K. H., Jadgal, N., & Bahrami, Y. (2026) · Drug Development Research · doi:10.1002/ddr.70229 · Cited by 17
“Combined with optimized assay design and validation steps, HTS surpasses traditional approaches in both efficiency and data quality (Macarron et al. 2011).”
InfluentialEine DNA‐kodierte Molekülbibliothek mit Elementen natürlicher Makrocyclen
Stress, C., Sauter, B., Schneider, L. A., Sharpe, T., & Gillingham, D. G. (2019) · Angewandte Chemie · doi:10.1002/ange.201902513 · Cited by 14
Computational prediction of frequent hitters in target-based and cell-based assays
Stork, C., Mathai, N., & Kirchmair, J. (2021) · Artificial Intelligence in the Life Sciences · doi:10.1016/j.ailsci.2021.100007 · Cited by 19
Optical-Switch Raman Spectroscopy for High Throughput Screening
Lee, S., Lee, K. H., Choi, Y., Kim, J. K., & Choi, W. J. (2023) · BioChip Journal · doi:10.1007/s13206-023-00113-3 · Cited by 14
CAPBO: A cost‐aware parallelized Bayesian optimization method for chemical reaction optimization
Liang, R., Hu, H., Han, Y., Chen, B., & Yuan, Z. (2023) · AIChE Journal · doi:10.1002/aic.18316 · Cited by 14
Horne, R. I., Wilson-Godber, J., Díaz, A. G., Brotzakis, Z. F., Seal, S., Gregory, R. C., Possenti, A., Chia, S., & Vendruscolo, M. (2024) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.3c01777 · Cited by 15
Paradigm shift required for translational research on the brain
Yoon, J. H., Lee, D., Lee, C., Cho, E., Lee, S., Cazenave‐Gassiot, A., Kim, K., Chae, S., Dennis, E. A., & Suh, P. (2024) · Experimental & Molecular Medicine · doi:10.1038/s12276-024-01218-x · Cited by 252
“These tools enable patient-centered and large-scale biomedical research 196 and can ultimately drive a new approach.”
Functionalised Ligand-Based Nanomaterial Drug Targeting Approaches for Colorectal Cancer Therapy
Dixit, A. A., Mandlik, D. S., & Mandlik, S. K. (2024) · Recent Advances in Drug Delivery and Formulation · doi:10.2174/0126673878301004240703073107 · Cited by 14
DrugTar improves druggability prediction by integrating large language models and gene ontologies
Borhani, N., Izadi, I., Motahharynia, A., Sheikholeslami, M., & Gheisari, Y. (2025) · Bioinformatics · doi:10.1093/bioinformatics/btaf360 · Cited by 15
“This has enabled the identification of extensive lists of proteins involved in various diseases, leading to the discovery of numerous proteins associated with disease pathways (Macarron et al. 2011).”
Fan, S., Pan, Z., Geng, Q., Li, X., Wang, Y., An, Y., Xu, Y. H., Tie, L., Pan, Y., & Li, X. (2013) · PLoS ONE · doi:10.1371/journal.pone.0067142 · Cited by 14
“Needless to say, with the rapid increase of experimental approaches, the advent of microarray facilitated large-scale monitoring of gene expression under different conditions at one time and enlightened roles of genes associated with infirmities in a systematic visualization [36,37].”
BackgroundIshoey, M., Petersen, R. G., Petersen, M. A., Wu, P., Clausen, M. H., & Nielsen, T. E. (2017) · Chemical Communications · doi:10.1039/c7cc02948a · Cited by 14
Glycohybrid molecules in medicinal chemistry: Present status and future prospective
Kumari, P., Narayana, C., Tiwari, G., & Sagar, R. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-816675-8.00011-7 · Cited by 14
Impact of Cyclization and Methylation on Peptide Penetration through Droplet Interface Bilayers
Faugeras, V., Duclos, O., Bazile, D., & Thiam, A. R. (2022) · Langmuir · doi:10.1021/acs.langmuir.2c00269 · Cited by 14
Design and Implementation of High-Throughput Screening Assays
Powell, D. J., Hertzberg, R., & Macarrón, R. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-3673-1_1 · Cited by 14
Self-citationLee, B., Nanishi, E., Levy, O., & Dowling, D. J. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15061766 · Cited by 14
“HTS has contributed to ~20–30% of late-stage clinical development candidates at several prominent pharmaceutical companies [37].”
BackgroundOn-DNA hydroalkylation of N -vinyl heterocycles via photoinduced EDA-complex activation
Sharique, M., Matsuo, B. T., Granados, A., Kim, S., Arshad, M., Oh, H., Wu, V. E., Huang, M., Csakai, A., Marcaurelle, L. A., et al. (2023) · Chemical Science · doi:10.1039/d3sc03731b · Cited by 14
Yoshida, Y., Fukuoka, K., Sakugawa, M., Kurogi, M., Hamamura, K., Hamasaki, K., Tsurusaki, F., Sotono, K., Nishi, T., Fukuda, T., et al. (2024) · Translational research · doi:10.1016/j.trsl.2024.02.004 · Cited by 16
Verteporfin inhibits TGF-β signaling by disrupting the Smad2/3–Smad4 interaction
Nong, J., Shen, S., Hong, F., Xiao, F., Meng, L., Li, P., Lei, X., & Chen, Y. (2024) · Molecular Biology of the Cell · doi:10.1091/mbc.e24-02-0073 · Cited by 14
“This property can interfere with widely used high-throughput screening such as alpha-screen and FRET (Scott and Goa, 2000; Macarron et al. , 2011).”
A chemistry wiki to facilitate and enhance compound design in drug discovery
Robb, G. R., McKerrecher, D., Newcombe, N. J., & Waring, M. J. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.09.002 · Cited by 14
Computational high-throughput screening of fluid permeability in heterogeneous fiber materials
Röding, M., Schüster, E., Logg, K., Lundman, M., Bergström, P., Hanson, C., Gebäck, T., & Lorén, N. (2016) · Soft Matter · doi:10.1039/c6sm01213b · Cited by 14
A Fluorescence-based Lymphocyte Assay Suitable for High-throughput Screening of Small Molecules
Fouda, A. E., Tahsini, M., Khodayarian, F., Al-nafisah, F., & Rafei, M. (2017) · Journal of Visualized Experiments · doi:10.3791/55199 · Cited by 14
Scalable static droplet array for biochemical assays based on concentration gradients
Lee, B., Jin, S. H., Noh, Y.-M., Jeong, S., Jeong, H., & Lee, C. (2018) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2018.07.076 · Cited by 14
Contribution of membrane transporters to chemotherapy‐induced cardiotoxicity
Uddin, M. E., Moseley, A., Hu, S., & Sparreboom, A. (2021) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13635 · Cited by 14
“Models based on hiPSCCMs are also amenable to genetic manipulation and high throughput screening (HTS) to allow rapid identification of novel transport modulators and select hit leads for further evaluation.(56) Alternatively, ex vivo evaluation of rodent cardiomyocytes directly obtained from animals of a desired gene…”
BackgroundSmall-Molecule Trk Agonists: Where Do We Go from Here?
Thompson, T. S., Sefiani, A., & Burgess, K. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02365 · Cited by 13
Bauer, J. A., Sysel, A. M., Heston, A. J., & Dunphy, M. (2025) · MethodsX · doi:10.1016/j.mex.2025.103469 · Cited by 13
“While high-throughput screening (HTS) platforms exist in academic and industry settings, they are often cost-prohibitive, technically demanding, and inaccessible to most undergraduate and high school laboratories [ 3 ].”
Computational approaches to druggable site identification: Current status and future perspective
Lin, A., Zhang, Z., Jiang, A., Li, K., Shi, Y., Yang, H., Zhang, J., Liu, R., Wang, Y., Glaviano, A., et al. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.10.032 · Cited by 15
“Concurrently, advancements in computational techniques such as high-throughput screening, molecular docking, and molecular dynamics simulations have enabled the large-scale screening of druggable targets 11 — 17 .”
Vitamin D analog calcitriol for breast cancer therapy; an integrated drug discovery approach
Nagaraj, B. S., Namboori, P. K. K., Swaroop, A. K., Sankaran, S., Raman, R., Natarajan, J., & Selvaraj, J. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2199866 · Cited by 14
“Several drug repurposing methodologies can be investigated, ranging from non-computational approaches to high-throughput screening (Macarron et al., 2011) and methods based on previous literature and experimental findings, e.g. target-based to computational approaches based.”
MethodInterfacing High-Throughput Electrosynthesis and Mass Spectrometric Analysis of Azines
Kulesa, K. M., Hirtzel, E. A., Nguyen, V. T., Freitas, D. P., Edwards, M. E., Yan, X., & Baker, L. A. (2024) · Analytical Chemistry · doi:10.1021/acs.analchem.4c01110 · Cited by 13
Chasing Red Herrings: Palladium Metal Salt Impurities Feigning KRAS Activity in Biochemical Assays
Gerstberger, T., Berger, H., Büttner, F. H., Gmachl, M., Kessler, D., Koegl, M., Lucas, S., Martin, L. J., Mayer, M., McConnell, D. B., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c02381 · Cited by 14
Ogbodo, J. O., Egba, S. I., Ikechukwu, G. C., Paul, P. C., Mba, J. O., Ugwu, O. P.-C., & Ezike, T. C. (2025) · Processes · doi:10.3390/pr13010154 · Cited by 13
“Robotic liquid handlers ensure precise dispensing of reagents, reducing variability and increasing reproducibility [92].”
DACMF-DTI: Dual attention embedded cross-modality fusion for drug-target interaction prediction
Wei, Z., Xiao, Z., Li, C., Wang, M., & Tang, C. (2025) · Knowledge-Based Systems · doi:10.1016/j.knosys.2025.114063 · Cited by 13
Yanagi, K., Komatsu, T., Ogihara, S., Okabe, T., Kojima, H., Nagano, T., Ueno, T., Hanaoka, K., & Urano, Y. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109311 · Cited by 13
Petruk, G., Puthia, M., Samsudin, F., Petrlová, J., Olm, F., Mittendorfer, M., Hyllén, S., Edström, D., Strömdahl, A., Diehl, C., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41702-y · Cited by 16
“For this, screening of vast amounts of chemical libraries has often been used, in combination with structure activity-based drug design in iterative processes in order to generate suitable high af fi nity compounds with the desired mode of action and low toxicity 41 .”
Introduction to Drug Repurposing: Exploring New Applications for Existing Drugs
Ahmad, Z., Rauf, A., Naz, S., & Hemeg, H. A. (2024) · Pharmaceutical science. · doi:10.5772/intechopen.113207 · Cited by 13
Recent developments in SAR visualization
Stumpfe, D., & Bajorath, J. (2016) · MedChemComm · doi:10.1039/c6md00108d · Cited by 14
Drugs as habitable planets in the space of dark chemical matter
Siramshetty, V. B., & Preißner, R. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.07.003 · Cited by 14
Salzer, E., Nixon, E., Drewes, G., Reinhard, F. B. M., Bergamini, G., & Rau, C. (2015) · SLAS TECHNOLOGY · doi:10.1177/2211068215595355 · Cited by 14
“Ideally, HTS compound libraries cover a substantial chemical space to enable the identification of new molecular entities, but the size of the screening campaign is affected by availability of resources.(4) Several areas are impacted by this, such as compound management, reagent supplies, and the testing of the compou…”
BackgroundShockley, K. R. (2016) · Scientific Reports · doi:10.1038/srep27897 · Cited by 13
“High-throughput screening of compounds for biological activity can play a fundamental role in the advancement of drug discovery 25 and in efforts to transform toxicology from a mostly observational science into a predictive science 26 .”
BackgroundSun, L., Xu, H., Ya, S., Liu, J., & Fan, L. (2019) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2019.01.009 · Cited by 13
Amos, B. K., Pook, V. G., & DeBolt, S. (2018) · Journal of Visualized Experiments · doi:10.3791/57393 · Cited by 12
Low-cost, autonomous microscopy using deep learning and robotics: A crystal morphology case study
Wilkinson, M. R., Dominguez, B. C., Wilson, C. C., & Martínez-Hernández, U. (2023) · Engineering Applications of Artificial Intelligence · doi:10.1016/j.engappai.2023.106985 · Cited by 13
Printed polymer platform empowering machine-assisted chemical synthesis in stacked droplets
Sun, Y., Zhao, Y., Xie, X., Li, H., & Feng, W. (2024) · Nature Communications · doi:10.1038/s41467-024-50768-1 · Cited by 12
Enabling target-aware molecule generation to follow multi objectives with Pareto MCTS
Yang, Y., Chen, G., Li, J., Li, J., Zhang, O., Zhang, X., Li, L., Hao, J., Wang, E., & Heng, P. (2024) · Communications Biology · doi:10.1038/s42003-024-06746-w · Cited by 16
Perspectives on Applications of 19F-NMR in Fragment-Based Drug Discovery
Li, Q., & Kang, C. (2024) · Molecules · doi:10.3390/molecules29235748 · Cited by 12
Copper-Mediated Three-Component Reaction for the Synthesis of N-Sulfonylamidine on DNA
Kwon, T. Y., Lee, Y., Cho, K., & Kim, H. J. (2025) · Organic Letters · doi:10.1021/acs.orglett.5c01034 · Cited by 12
Takáč, P., Michalková, R., Čižmáriková, M., Bedlovičová, Z., Balážová, Ľ., Megyesi, Š. L., Mačeková, Z., Takáčová, G., Moreno-Borrallo, A., Ruiz‐Hernández, E., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26115344 · Cited by 14
Zhang, K., Bouakher, A. E., Levaïque, H., Bignon, J. S., Retailleau, P., Alami, M., & Hamzé, A. (2020) · Advanced Synthesis & Catalysis · doi:10.1002/adsc.202000553 · Cited by 12
Berker, Y., ElHarouni, D., Peterziel, H., Fiesel, P., Witt, O., Oehme, I., Schlesner, M., & Oppermann, S. (2022) · IEEE Transactions on Medical Imaging · doi:10.1109/tmi.2022.3205554 · Cited by 15
“F UNCTIONAL drug testing is an important step in drug discovery and drug repurposing [1], [2], [3], [4] which also receives increasing attention in precision medicine [5], [6], [7].”
BackgroundWu, X., Chen, Y., Lu, W., Jin, R., & Lu, X. (2022) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.2c00421 · Cited by 12
The European lead factory—an experiment in collaborative drug discovery
Laverty, H., Orrling, K. M., Giordanetto, F., Poinot, M., Ottow, E., Rijnders, T., Tzalis, D., & Jaroch, S. (2015) · JOURNAL OF MEDICINES DEVELOPMENT SCIENCES · doi:10.18063/jmds.v1i1.120 · Cited by 12
Protein complexes as psychiatric and neurological drug targets
Kato, A., & Witkin, J. M. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.01.018 · Cited by 13
“TDD approaches test hypotheses concerning specific gene/protein targets utilizing a plethora of methods and new technologies including automation, structural biology, and advanced chemistry technologies [14].”
BackgroundZhou, M., Li, R., Liao, X.-M., Wang, Z., Xu, G., Gong, Z., Lü, Y., He, X., Li, Y., Wang, Y., et al. (2018) · Journal of Separation Science · doi:10.1002/jssc.201701370 · Cited by 12
FusionPathway: Prediction of pathways and therapeutic targets associated with gene fusions in cancer
Wu, C.-C., Beird, H. C., Zhang, J., & Futreal, P. A. (2018) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1006266 · Cited by 12
From Computers to Bedside: Computational Chemistry Contributing to FDA Approval
Athanasiou, C., & Cournia, Z. (2018) · Methods and principles in medicinal chemistry · doi:10.1002/9783527806836.ch7 · Cited by 21
Wu, Q., Sun, Z., Chen, Z., Liu, J., Ding, H., Luo, C., Wang, M., & Du, D. (2022) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2022.128883 · Cited by 12
3D bioprinting – Flow cytometry as analytical strategy for 3D cell structures
Gretzinger, S., Beckert, N., Gleadall, A., Lee‐Thedieck, C., & Hubbuch, J. J. (2018) · Bioprinting · doi:10.1016/j.bprint.2018.e00023 · Cited by 12
Bibič, L., Herzig, V., King, G. F., & Stokes, L. (2019) · Journal of Natural Products · doi:10.1021/acs.jnatprod.9b00410 · Cited by 12
Drug discovery and chemical probing in Drosophila
Millet-Boureima, C., Selber‐Hnatiw, S., & Gamberi, C. (2020) · Genome · doi:10.1139/gen-2020-0037 · Cited by 14
Wang, Y., Wang, Z., Sadeh, G., Zancato, L., Achille, A., Karypis, G., & Rangwala, H. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.29.620988 · Cited by 19
“We summarize the key hyperparameters in table 7.”
McNerlin, C., Guan, F., Bronk, L., Lei, K., Grosshans, D., Young, D. W., Gaber, M. W., & Maletic-Savatic, M. (2022) · Life Sciences in Space Research · doi:10.1016/j.lssr.2022.07.007 · Cited by 11
High-Throughput Cell Toxicity Assays
Murray, D., McWilliams, L. J., & Wigglesworth, M. J. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-3673-1_16 · Cited by 11
Metzger, J., Nolte, A. M., Uhde, A., Hewicker‐Trautwein, M., & Distl, O. (2017) · BMC Genomics · doi:10.1186/s12864-017-3737-z · Cited by 12
Chemical genetics and strigolactone perception
Lumba, S., Bunsick, M., & McCourt, P. (2017) · F1000Research · doi:10.12688/f1000research.11379.1 · Cited by 11
Chemical Kinetic Strategies for High‐Throughput Screening of Protein Aggregation Modulators
Sárkány, Z., Rocha, F. A., Damas, A. M., Macedo‐Ribeiro, S., & Martins, P. M. (2019) · Chemistry - An Asian Journal · doi:10.1002/asia.201801703 · Cited by 14
Finding new scaffolds of JAK3 inhibitors in public database: 3D-QSAR models & shape-based screening
Gadhe, C. G., Lee, E.-H., & Kim, M. (2015) · Archives of Pharmacal Research · doi:10.1007/s12272-015-0607-6 · Cited by 11
“However, this technology also produces false positive hits or identifies undesirable hits in view of drug likeness (e.g., stability, solubility, and toxicity; Feng et al. 2005; Hughes et al. 2011; Macarron et al. 2011).”
Background
Metadata
- Authors
- Macarron, R., Banks, M. N., Bojanic, D., Burns, D. J., Cirovic, D. A., Garyantes, T., Green, D. V. S., Hertzberg, R. P., Janzen, W. P., Paslay, J. W., Schopfer, U., & Sittampalam, G. S.
- Affiliations
- Bristol-Myers Squibb (United States) (US)
- Novartis (United States) (US)
- Abbott (United States) (US)
- Sanofi (France) (FR)
- GlaxoSmithKline (United Kingdom) (GB)
- GlaxoSmithKline (United States) (US)
- University of North Carolina at Chapel Hill (US)
- The University of Kansas Cancer Center (US)
- Novartis (Switzerland) (CH)
- Pfizer (United States) (US)
- Venue
- Nature Reviews Drug Discovery
- Published
- 2011-03
- Volume
- 10
- Issue
- 3
- Pages
- 188-195
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2031441006
- Cited by
- 1,364
- References
- 65
- Citations by year
- 2026: 113 · 2025: 117 · 2024: 99 · 2023: 103 · 2022: 82 · 2021: 107 · 2020: 106 · 2019: 77 · 2018: 105 · 2017: 87 · 2016: 96 · 2015: 64 · 2014: 61 · 2013: 73 · 2012: 54
- FWCI
- 6.80
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Keywords
- high-throughput screening, drug discovery, chemical biology
- MeSH terms
- Animals, Drug Evaluation, Preclinical, Humans, Drug Design, Biomedical Research, Small Molecule Libraries
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.